

Eurofins Scientific

712.40 Eur
+1.86%

ISIN: FR0000038259
Ticker: ERF

Sector: Health Services
Stock exchange: Euronext
Market capitalization: 13.53 billion

Key Metrics:

Performance YTD: 44.15%
Estimated 2020 P/E: 30.47

Earning per share: 10.9
Price to book: 7

Net Debt: 3.63 billion
Return on Equity: 0.112

Fundamental analysis summary

Active in external growth between 2017 and 2018, Eurofins can now focus on improving its margin and profitability. Since 2015, it has achieved a CAGR of 26% in revenues but a profit that is down from 2018. However, the company claims to have been strongly impacted in 2019 by a new IFRS standard and several cyber-attacks. Half of Eurofins' assets are in goodwill which is likely to contain patents and premiums of acquired companies. The results for 2020 are good and growing compared to the previous year.

Technical analysis summary

Growing curve. Since the beginning of August Eurofins has recorded a 30% gain. Unfortunately, we are reaching the overbought territories with an ROI of 77 in daily and 75 in weekly but with the current market conditions it is not surprising to see such levels.

Chart - Year To Date

